{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:41Z","timestamp":1788881141731,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.neuropharm.2024.109889","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T07:53:46Z","timestamp":1708588426000},"page":"109889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-4133","authenticated-orcid":false,"given":"Mathieu","family":"Fonteneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Brugoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Jaccaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Donello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-4273","authenticated-orcid":false,"given":"Julie","family":"Le Merrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-0067","authenticated-orcid":false,"given":"J\u00e9r\u00f4me AJ.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.109889_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113165","article-title":"Correlation of distinct behaviors to the modified expression of cerebral Shank 1,3 and BDNF in two autistic animal models","volume":"404","author":"Al\u00f2","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM","article-title":"Diagnostic and statistical manual of mental disorders: DSM-5TM","year":"2013"},{"key":"10.1016\/j.neuropharm.2024.109889_bib3","first-page":"CD013457","article-title":"The effectiveness and adverse effects of D\u2010cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder","volume":"2021","author":"Aye","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2024.109889_bib4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neuron.2019.02.041","article-title":"A synaptic perspective of fragile X syndrome and autism spectrum disorders","volume":"101","author":"Bagni","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109889_bib5","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/j.biopsych.2019.03.884","article-title":"S133. AGN-241751, an orally bioavailable positive NMDA receptor modulator, exhibits rapid and sustained antidepressant-like effects in rodents","volume":"85","author":"Banerjee","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109889_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nn.4319","article-title":"SHANK3 controls maturation of social reward circuits in the VTA","volume":"19","author":"Bariselli","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib7","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/npp.2014.59","article-title":"Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity","volume":"39","author":"Becker","year":"2014","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib8","first-page":"1","article-title":"Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice","author":"Becker","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109889_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuron.2007.07.035","article-title":"Rapid bidirectional switching of synaptic NMDA receptors","volume":"55","author":"Bellone","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109889_bib10","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1038\/s41467-019-11891-6","article-title":"Altered dendritic spine function and integration in a mouse model of fragile X syndrome","volume":"10","author":"Booker","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.109889_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/cercor\/bht237","article-title":"Rescue of NMDAR-dependent synaptic plasticity in Fmr1 knock-out mice","volume":"25","author":"Bostrom","year":"2015","journal-title":"Cereb. Cortex N. Y. N"},{"key":"10.1016\/j.neuropharm.2024.109889_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/jnc.14845","article-title":"NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor","volume":"152","author":"Bowers","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.109889_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109889_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ijnp\/pyac043","article-title":"Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects","volume":"25","author":"Burgdorf","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2013.05.003","article-title":"D-Cycloserine improves sociability in the BTBR T+ Itpr3tf\/J mouse model of autism spectrum disorders with altered Ras\/Raf\/ERK1\/2 signaling","volume":"96","author":"Burket","year":"2013","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2024.109889_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41422-020-00439-9","article-title":"CaMKII\u03b1-driven, phosphatase-checked postsynaptic plasticity via phase separation","volume":"31","author":"Cai","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbr.2016.09.003","article-title":"Downregulation of glutamatergic and GABAergic proteins in valproric acid associated social impairment during adolescence in mice","volume":"316","author":"Chau","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pnpbp.2017.11.016","article-title":"PSD95: a synaptic protein implicated in schizophrenia or autism?","volume":"82","author":"Coley","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109889_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0896-6273(03)00687-1","article-title":"Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression","volume":"40","author":"Colledge","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109889_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tins.2020.03.005","article-title":"Prenatal origins of ASD: the when, what, and how of ASD development","volume":"43","author":"Courchesne","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.tig.2017.07.008","article-title":"Multifarious functions of the fragile X mental retardation protein","volume":"33","author":"Davis","year":"2017","journal-title":"Trends Genet. TIG"},{"key":"10.1016\/j.neuropharm.2024.109889_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-022-01317-1","article-title":"Chronic sodium bromide treatment relieves autistic-like behavioral deficits in three mouse models of autism","author":"Derieux","year":"2022","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib23","first-page":"101","article-title":"From mouse to man: N-Methyl-d-Aspartic acid receptor activation as a promising pharmacotherapeutic strategy for autism spectrum disorders","volume":"107","author":"Deutsch","year":"2023","journal-title":"Med. Clin."},{"key":"10.1016\/j.neuropharm.2024.109889_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ijnp\/pyy101","article-title":"Positive N-Methyl-D-Aspartate receptor modulation by rapastinel promotes rapid and sustained antidepressant-like effects","volume":"22","author":"Donello","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1542\/peds.2012-0683","article-title":"Medications for adolescents and young adults with autism spectrum disorders: a systematic review","volume":"130","author":"Dove","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2024.109889_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1113\/JP280875","article-title":"Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential","volume":"600","author":"Geoffroy","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0169-328X(99)00100-X","article-title":"NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A","volume":"69","author":"Goebel","year":"1999","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/09540261.2018.1458706","article-title":"An update on pharmacotherapy of autism spectrum disorder in children and adolescents","volume":"30","author":"Goel","year":"2018","journal-title":"Int. Rev. Psychiatry Abingdon Engl."},{"key":"10.1016\/j.neuropharm.2024.109889_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040370","article-title":"Rapid redistribution of synaptic PSD-95 in the neocortex in vivo","volume":"4","author":"Gray","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.neuropharm.2015.02.013","article-title":"Essential role of GluD1 in dendritic spine development and GluN2B to GluN2A NMDAR subunit switch in the cortex and hippocampus reveals ability of GluN2B inhibition in correcting hyperconnectivity","volume":"93","author":"Gupta","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109889_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuropharm.2016.07.037","article-title":"Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences","volume":"112","author":"Hackos","year":"2017","journal-title":"Neuropharmacology, Ionotropic Glutamate Receptors"},{"key":"10.1016\/j.neuropharm.2024.109889_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41398-018-0155-1","article-title":"Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models","volume":"8","author":"Horder","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109889_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuron.2013.03.016","article-title":"Modeling autism by SHANK gene mutations in mice","volume":"78","author":"Jiang","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109889_bib34","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1542\/peds.2007-2361","article-title":"Identification and evaluation of children with autism spectrum disorders","volume":"120","author":"Johnson","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2024.109889_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ijnp\/pyx096","article-title":"NYX-2925 is a novel NMDA receptor-specific spirocyclic-\u03b2-lactam that modulates synaptic plasticity processes associated with learning and memory","volume":"21","author":"Khan","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12035-014-8987-z","article-title":"MeCP2 modulates sex differences in the postsynaptic development of the valproate animal model of autism","volume":"53","author":"Kim","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jnc.12147","article-title":"Male-specific alteration in excitatory post-synaptic development and social interaction in pre-natal valproic acid exposure model of autism spectrum disorder","volume":"124","author":"Kim","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.109889_bib38","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1073\/pnas.1013855108","article-title":"Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome","volume":"108","author":"Krueger","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2024.109889_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biopsych.2023.05.008","article-title":"Balance between projecting neuronal populations of the nucleus accumbens controls social behavior in mice","volume":"95","author":"Le Merrer","year":"2024","journal-title":"Biol. Psychiatry, Circuit Mechanisms of Social Behavior and Autism"},{"key":"10.1016\/j.neuropharm.2024.109889_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.biopsych.2016.05.011","article-title":"Excitation\/inhibition imbalance in animal models of autism spectrum disorders","volume":"81","author":"Lee","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109889_bib41","article-title":"The amygdala excitatory\/inhibitory balance in a valproate-induced rat autism model","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.109889_bib42","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1523\/JNEUROSCI.23-17-06876.2003","article-title":"Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala","volume":"23","author":"Lopez de Armentia","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib43","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/cercor\/bhv031","article-title":"Age-dependent long-term potentiation deficits in the prefrontal cortex of the Fmr1 knockout mouse model of fragile X syndrome","volume":"26","author":"Martin","year":"2016","journal-title":"Cereb. Cortex N. Y. N"},{"key":"10.1016\/j.neuropharm.2024.109889_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fncel.2014.00023","article-title":"Late onset deficits in synaptic plasticity in the valproic acid rat model of autism","volume":"8","author":"Martin","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10802-012-9668-x","article-title":"Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders","volume":"41","author":"Mazurek","year":"2013","journal-title":"J. Abnorm. Child Psychol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib46","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s41380-020-00859-4","article-title":"Consequences of NMDA receptor deficiency can be rescued in the adult brain","volume":"26","author":"Mielnik","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109889_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.nbd.2005.08.019","article-title":"The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo","volume":"21","author":"Mientjes","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2024.109889_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-015-0062-8","article-title":"A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders","volume":"7","author":"Minshawi","year":"2016","journal-title":"Mol. Autism."},{"key":"10.1016\/j.neuropharm.2024.109889_bib49","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.neubiorev.2011.06.006","article-title":"A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism","volume":"35","author":"Moskal","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109889_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000341786","article-title":"Effects of rat prenatal exposure to valproic acid on behaviour and neuro-anatomy","volume":"34","author":"Mychasiuk","year":"2012","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fncel.2015.00100","article-title":"Functional and structural deficits at accumbens synapses in a mouse model of Fragile X","volume":"9","author":"Neuhofer","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1126\/science.1227764","article-title":"Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders","volume":"338","author":"O'Roak","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2024.109889_bib53","doi-asserted-by":"crossref","first-page":"8296","DOI":"10.1038\/srep08296","article-title":"Association of genetic variants of GRIN2B with autism","volume":"5","author":"Pan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.109889_bib54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","article-title":"Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists","volume":"150","author":"Papouin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.109889_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature09965","article-title":"Shank3 mutant mice display autistic-like behaviours and striatal dysfunction","volume":"472","author":"Pe\u00e7a","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.109889_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/B978-0-444-64012-3.00024-1","article-title":"The psychopharmacology of autism spectrum disorder and Rett syndrome","volume":"165","author":"Persico","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib57","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of D-cycloserine in subjects with autistic disorder","volume":"161","author":"Posey","year":"2004","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109889_bib58","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41380-020-0796-3","article-title":"Cell-type specific modulation of NMDA receptors triggers antidepressant actions","volume":"26","author":"Pothula","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109889_bib59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41386-020-00882-7","article-title":"Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons","volume":"46","author":"Pothula","year":"2021","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib60","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ridd.2012.12.022","article-title":"Reactive\/proactive aggression and affective\/cognitive empathy in children with ASD","volume":"34","author":"Pouw","year":"2013","journal-title":"Res. Dev. Disabil."},{"key":"10.1016\/j.neuropharm.2024.109889_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41398-018-0247-y","article-title":"Back-translating behavioral intervention for autism spectrum disorders to mice with blunted reward restores social abilities","volume":"8","author":"Pujol","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109889_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/aur.2066","article-title":"Hypothesis-driven investigations of diverse pharmacological targets in two mouse models of autism","volume":"12","author":"Rhine","year":"2019","journal-title":"Autism Res. Off. J. Int. Soc. Autism Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib63","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.1073\/pnas.0704391104","article-title":"Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid","volume":"104","author":"Rinaldi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2024.109889_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11065-012-9212-3","article-title":"Childhood epilepsy and autism spectrum disorders: psychiatric problems, phenotypic expression, and anticonvulsants","volume":"22","author":"Robinson","year":"2012","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2024.109889_bib65","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00702-014-1216-0","article-title":"The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment","volume":"121","author":"Rojas","year":"2014","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.neuropharm.2024.109889_bib66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/aur.1264","article-title":"Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes","volume":"6","author":"Saunders","year":"2013","journal-title":"Autism Res. Off. J. Int. Soc. Autism Res."},{"key":"10.1016\/j.neuropharm.2024.109889_bib67","doi-asserted-by":"crossref","first-page":"25479","DOI":"10.1074\/jbc.M109.042663","article-title":"Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities","volume":"284","author":"Sch\u00fctt","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2024.109889_bib68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/368144a0","article-title":"Changing subunit composition of heteromeric NMDA receptors during development of rat cortex","volume":"368","author":"Sheng","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.109889_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000717","article-title":"Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice","volume":"18","author":"Shin","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib70","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ng.3792","article-title":"Targeted sequencing identifies 91 neurodevelopmental disorder risk genes with autism and developmental disability biases","volume":"49","author":"Stessman","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2024.109889_bib71","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1038\/tp.2011.52","article-title":"Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia","volume":"1","author":"Tarabeux","year":"2011","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109889_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.12.024","article-title":"Prenatal valproate in rodents as a tool to understand the neural underpinnings of social dysfunctions in autism spectrum disorder","volume":"159","author":"Tartaglione","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109889_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2015.12.025","article-title":"Reversal of social deficits by subchronic oxytocin in two autism mouse models","volume":"105","author":"Teng","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109889_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neubiorev.2020.09.017","article-title":"The neuroligins and the synaptic pathway in Autism Spectrum Disorder","volume":"119","author":"Trobiani","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109889_bib75","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cell.2012.11.040","article-title":"Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95","volume":"151","author":"Tsai","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.109889_bib76","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1016\/j.celrep.2018.05.087","article-title":"NGL-2 deletion leads to autistic-like behaviors responsive to NMDAR modulation","volume":"23","author":"Um","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2024.109889_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.neuropsych.13070155","article-title":"A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders","volume":"27","author":"Urbano","year":"2015","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-017-1736-4","article-title":"Autism spectrum disorder: neuropathology and animal models","volume":"134","author":"Varghese","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib79","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/npp.2011.185","article-title":"Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments","volume":"37","author":"Veenstra-VanderWeele","year":"2012","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109889_bib80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-neuro-071714-033821","article-title":"Glutamate synapses in human cognitive disorders","volume":"38","author":"Volk","year":"2015","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1362361311431951","article-title":"Social anxiety mediates the effect of autism spectrum disorder characteristics on hostility in young adults","volume":"16","author":"White","year":"2012","journal-title":"Autism Int. J. Res. Pract."},{"key":"10.1016\/j.neuropharm.2024.109889_bib82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnint.2013.00051","article-title":"Sensory-motor problems in autism","volume":"7","author":"Whyatt","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109889_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109782","article-title":"Molecular architecture of postsynaptic interactomes","volume":"76","author":"Wilkinson","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2024.109889_bib84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-017-0116-1","article-title":"d-Cycloserine enhances durability of social skills training in autism spectrum disorder","volume":"8","author":"Wink","year":"2017","journal-title":"Mol. Autism."},{"key":"10.1016\/j.neuropharm.2024.109889_bib85","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature11208","article-title":"Autistic-like social behaviour in Shank 2-mutant mice improved by restoring NMDA receptor function","volume":"486","author":"Won","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.109889_bib86","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.neuropharm.2008.08.018","article-title":"A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral\u2013CA1 synapses in hippocampus","volume":"55","author":"Zhang","year":"2008","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T09:10:00Z","timestamp":1720602600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082400056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":86,"alternative-id":["S002839082400056X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109889","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109889"}}